We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.055 | -2.40% | 2.24 | 2.20 | 2.28 | 2.28 | 2.21 | 2.21 | 734,558 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.00 | 7.6M |
From Apr 2019 to Apr 2024
TIDMIMM
RNS Number : 0005A
Immupharma PLC
21 December 2017
21 DECEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 900,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to certain of its consultants who have been directly involved in Lupuzor(TM)'s successful development to date, representing 0.679% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis (the "Options"). The Options were granted upon the recommendation of the Company's remuneration committee.
The exercise price for the Options is 153 pence being the closing middle market share price on 20 December 2017. The Options will vest subject to certain conditions after three years and are exercisable between three and ten years from the date of grant.
Total Share Options
The total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The total options outstanding that have been granted to non-employees and consultants is 6,085,000. The total warrants outstanding is 153,850. Taken altogether, there are currently 16,368,850 outstanding options and warrants, representing 12.35% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.
This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.
Ends
For further information, please contact:
ImmuPharma plc (www.immupharma.co.uk) --------------------------------------- --------------------- Tim McCarthy, Chairman Lisa Baderoon, Head of Investor +44 (0) 20 7152 Relations 4080 Twitter: @immupharma +44 (0) 7721 413496 --------------------------------------- --------------------- Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, Corporate Finance David Hignell, Corporate Finance Jamie Spotswood, Corporate Finance +44 (0) 20 3861 Rob Rees, Corporate Broking 6625 --------------------------------------- ---------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTMBPTMBJTBAR
(END) Dow Jones Newswires
December 21, 2017 02:05 ET (07:05 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
